Labor Market Pulse · Life Sciences · September 2026
Life Sciences Labor Market Report: Raleigh-Cary, NC MSA — September 2026
Raleigh biomanufacturing boom outruns its own talent pipeline.
Raleigh-Cary's 3.1% unemployment rate — the lowest among NC metros — collides with Amgen's $1B and J&J's $2B expansions, while advertised Validation Engineer pay falls to $98,188 even as the national rate climbs.
Free archive edition. Published by WageScape as sent to subscribers; data as of September 2026.
Key indicators
- Raleigh-Cary unemployment rate: 3.1% — vs 4.1% national, lowest tied among NC metros
- NC life sciences capital investment: $3B+ — Amgen ($1B) + J&J ($2B) announced expansions
- Statewide wage growth deceleration: ~4% YoY — down from 6%+ peak in 2022
- NC WARN notices, 2026 YTD: 61 notices / 5,753 workers — 13 filings, 1,336 workers in last 90 days
Key takeaways
Biomanufacturing capacity is outpacing the specialized talent behind it.
Amgen's Holly Springs expansion and J&J's new Wilson County campus add nearly 800 announced jobs, but NC Life Sciences Organization's Q3 forum explicitly questioned workforce sufficiency. Entry-level BioWork graduates can staff operator lines at $67,000 starting pay, but quality, validation, and regulatory seats behind those lines remain the harder fill.
Validation Engineer pay is falling locally while the national trend climbs.
Metro advertised pay for Validation Engineers dropped significantly to $98,188 even as the national median rose moderately to $108,377, an unusual divergence given the metro's manufacturing buildout. This may reflect employers routing validation work to CDMOs or lower-cost contract staff rather than building internal headcount.
Clinical Data Manager pay softened, but don't read it as reduced demand.
Metro pay for Clinical Data Manager fell significantly to $104,102, below the national median of $123,031, even as CRA pay rose sharply locally. The gap is consistent with employers shifting data management work to CROs or centralized remote teams rather than local clinical operations, a build-vs-outsource signal worth tracking in CRO contract renewals.
Regulatory Affairs scarcity is a national story playing out locally.
VP-level Regulatory Affairs compensation nationally ranges $320K-$580K amid acute global scarcity, while metro Regulatory Affairs Specialist pay holds stable at $119,476. Stability at the specialist tier alongside senior-level premium escalation suggests the real retention risk sits in the experienced-but-not-yet-VP cohort most exposed to recruitment from Amgen and J&J's new sites.
Median advertised pay by role — Raleigh-Cary, NC MSA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist | $109,700 | $176,464 | $181,464 | Significant increase | $131,354 |
| Clinical Research Associate | $80,080 | $114,146 | $122,155 | Significant increase | $90,956 |
| Lab Technician | $37,457 | $41,600 | $51,233 | Significant decline | $47,402 |
| Regulatory Affairs Specialist | $99,356 | $119,476 | $132,201 | Stable | $104,000 |
| Clinical Data Manager | $96,408 | $104,102 | $122,214 | Significant decline | $123,031 |
| Biostatistician | $120,000 | $141,773 | $150,842 | Moderate increase | $133,322 |
| Validation Engineer | $89,285 | $98,188 | $107,129 | Significant decline | $108,377 |
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Raleigh-Cary's 3.1% August unemployment rate ties the metro for the lowest among NC metros and sits a full point below the national 4.1% reading, as biomanufacturing expansion from Amgen's $1B Holly Springs project and J&J's $2B Wilson County biologics campus pulls skilled talent into an already thin pool. Statewide wage growth has decelerated to roughly 4% year-over-year from a 2022 peak above 6%, meaning employers are competing harder for scarce talent even as across-the-board pay increases become harder to justify.
What it means
Scientific and regulatory headcount planning now runs into a structural wall: NC Life Sciences Organization's own September forum questioned whether the state's biomanufacturing workforce can keep pace with Amgen, J&J, and CDMO expansion, while entry-level operator pipelines like Wilson County's BioWork program feed manufacturing floors but leave specialized scientific, quality, and regulatory roles under-supplied. Mismatched local pay signals — Clinical Research Associate advertised pay up significantly to $114,146 against a shrinking Validation Engineer rate of $98,188 — suggest clinical-stage functions are pulling budget away from manufacturing-support roles. Consider reviewing whether current headcount plans assume talent availability that the regional pipeline cannot actually deliver, particularly for quality and validation roles feeding new biologics capacity.
Looking ahead
Worth watching: October 20 brings the first official September unemployment release for NC and Raleigh-Cary. A further drop below 3.1% would tighten an already constrained labor pool just as Amgen and J&J ramp hiring.
Emerging pressure point: Watch whether Kincellis Advanced Therapies' CDMO consolidation and CSO hire from Resilience/Lyell/Pfizer signals broader cell therapy CDMO rollups in the region, which could shift build-vs-outsource economics for gene and cell therapy manufacturing.
Early indicator: Track whether Wilson Community College's pending $36.4M BioWork hub expansion accelerates operator-level supply fast enough to ease pressure on J&J and Fresenius Kabi staffing, or whether it simply keeps pace with new capacity coming online.
Potential inflection point: National September layoff announcements at BioMarin (117 roles) and Bristol Myers (265 roles) haven't yet produced comparable NC WARN filings; monitor whether displaced specialized talent from these consolidations begins surfacing in the Raleigh-Cary candidate pool.
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.